



## COVID-19 VACCINES

EVIDENCE IN BRIEF

# VACCINATING PREGNANT WOMEN

### PROTECTING MOTHER AND CHILD

COVID-19 infection during pregnancy puts women at increased risk for severe illness from COVID-19 and complications such as preterm birth. Rigorous emerging data demonstrate the vaccines work as well in pregnant women as in non pregnant people, showing similar high vaccine effectiveness against COVID-19 infection, disease, hospitalization, and death.

Given the substantial risks from COVID-19 during pregnancy, WHO conveys that it is critical to ensure pregnant women, and those planning to become pregnant, have access to WHO EUL-approved COVID-19 vaccines as soon as available to protect their health and that of their babies.



Read the [WHO interim recommendations on COVID-19 vaccination of pregnant women here](#) and [the WHO Q&A on COVID-19 vaccines and pregnancy here](#)

### EXPLORE THE DATA

#### VACCINE EFFECTIVENESS (95% CI) \*

Against infection	Against symptomatic disease	Against hospitalization	PREDOMINANT VARIANTS OF CONCERN <sup>1</sup>	STUDY REFERENCE
<b>AMONG PREGNANT WOMEN</b>				
<b>Pfizer</b>				
54% (33-69) <sup>#</sup>			Original, Alpha	Goldstein, <i>JAMA</i> , 2021
78% (57-89) <sup>~</sup>				
96% (89-100) <sup>^</sup>	97% (91-100) <sup>^</sup>	89% (43-100) <sup>^</sup>	Original, Alpha	Dagan, <i>nature medicine</i> , 2021
87.7% (43.5-97.3)			Alpha, Beta	Butt, <i>JCI</i> , 2021
<b>Sinovac</b>				
	41% (27-52.2)		Gamma, Delta	Paixao, <i>SSRN</i> , 2021
<b>AMONG HEALTHCARE WORKERS THAT ARE PREGNANT</b>				
<b>Any mRNA</b>				
	77.1% (32.2-92.2) <sup>†</sup>		Alpha	Pilishvili, <i>NEJM</i> , 2021

\* VE assessed 14 days after 2nd dose, unless otherwise indicated

<sup>#</sup> VE assessed 11-27 days post 1st dose, including some with dose 2

<sup>~</sup> VE assessed 28+ days post 1st dose, including some with dose 2

<sup>^</sup> VE assessed 7-56 days after 2nd dose

<sup>†</sup> VE assessed 14+ days through dose 2 or later (at least one dose)

<sup>1</sup> Predominant variant identified by study authors or based on <https://outbreak.info/location-report>. Refer to cited study or report for more details.

**DISCLAIMER:** This table is not a comprehensive summary of all available vaccine effectiveness data and studies for other vaccines and mixed schedules are ongoing; visit the links below for additional studies and data. As a result, this brief does not report on all available COVID-19 vaccines. Data may not reflect most recent variants of concern and will be updated as studies become available.

### RESOURCES

Full studies and supplemental data are available at <https://bit.ly/covid-vax-evidence> and <https://VIEW-hub.org/covid-19/effectiveness-studies>

VERSION: FEBRUARY 18, 2022



### About CHOICES

For more information or to request CHOICES technical assistance, visit [www.jhsph.edu/ivac/projects/choices/](http://www.jhsph.edu/ivac/projects/choices/)